Just caught wind of a pretty major move in the pharma manufacturing space. Lonza is offloading its Capsules & Health Ingredients business to Lone Star Funds in what looks like a CHF 2.3 billion deal - that's roughly US$3 billion for those tracking in dollars.

What's interesting here is how this fits into their bigger strategic play. They're getting CHF 1.7 billion upfront (about US$2.2 billion) but keeping a 40% stake in the business with preferential rights on any future exit. When you factor in those future returns, they're looking at total proceeds hitting CHF 3 billion or above - basically US$4 billion territory. Pretty solid structure honestly.

The money's earmarked for organic growth, strategic bolt-on acquisitions, and they're committing CHF 500 million to share buybacks. This is clearly part of their One Lonza Strategy that they laid out back in December - basically transforming into a pure-play CDMO operation.

What caught my attention is the bigger picture. Beyond the capsules business, they're also divesting their Personalized Medicines unit, spinning off MODA software, and selling the small molecules micronization site in Monteggio. It's a pretty comprehensive portfolio cleanup. The whole thesis seems to be: double down on what works in CDMO, strip away the rest, improve margins, and create a leaner operation focused on sustainable growth.

They're running three integrated CDMO platforms now powered by their Lonza Engine - leveraging advanced science and smart tech for complex pharma work. Seems like they're betting that specialization in this space is where the real value creation happens.

Expecting the CHI transaction to close in the second half of 2026 pending regulatory approvals. Worth watching how this reshapes the CDMO landscape.